← FDA DRUG APPROVALS

FDA ANDA · ANDA085248

TRICHLORMETHIAZIDE W/ RESERPINE

Sponsor: WATSON LABS

APPLICATION
ANDA085248
TYPE
ANDA
LATEST ACTION
1987-09-30
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

TRICHLORMETHIAZIDE W/ RESERPINEDiscontinued
RESERPINE 0.1MG, TRICHLORMETHIAZIDE 4MG · TABLET · ORAL

Approval history

1987-09-30Manufacturing (CMC) · Supplement 19AP
1983-04-13Manufacturing (CMC) · Supplement 15AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →